Analysis of Neglected Tropical Disease Drug and Vaccine Development Pipelines to Predict Issuance of FDA Priority Review Vouchers over the Next Decade

PLoS Neglected Tropical Diseases

Volumn 6, Issue 10, 2012, Pages

  Stefanakis, Rianna ^a   Robertson, Andrew S ^a   Ponder, Elizabeth L ^a   Moree, Melinda ^a  

^a BIO Ventures for Global Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CHIMERIVAX; MOXIDECTIN; PXVX 0200; RTS S/AS 01; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; AWARDS AND PRIZES; CHOLERA; DECISION TREE; DENGUE; DRUG ANALYSIS; DRUG APPROVAL; DRUG RESEARCH; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEALTH PROGRAM; HUMAN; MALARIA; ONCHOCERCIASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY REVIEW VOUCHER PROGRAM; TUBERCULOSIS;

COMMUNICABLE DISEASES; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; NEGLECTED DISEASES; TROPICAL MEDICINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINES;

EID: 84869029528     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001803     Document Type: Article

References (24)

1. Hotez P, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357(10): 1018-1027.
2. Chirac P, Torreele E, (2006) Global Framework on essential health R&D. Lancet 367: 15600-15601.
3. US Food and Drug Administration (FDA) (2008) FDA draft guidance for industry: tropical disease priority review vouchers. Washington (D.C.): Government Printing Office. October 2008.
4. Priority Review to Encourage Treatments for Tropical Diseases. Title 21, U.S. Code, Pts. 360n, 2007 ed. Available: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/FullTextofFDAAALaw/default.htm. Accessed 4 January 2012.
5. Ridley D, Grabowski H, Moe J, (2006) Developing drugs for developing countries. Health Affairs 25 (2):: 313-324.
6. Noor W (2009) Placing value on FDA's priority review vouchers. InVivo 27. Number 8, September 2009.
7. BIO Ventures for Global Health (2011) Global health primer. Available: http://www.bvgh.org/GlobalHealthPrimer.aspx (last updated: October 18, 2011). Accessed 15 July 2011.
8. Glickman SW, Rasiel EB, Hamilton CD, Kubataev A, (2006) A portfolio model of drug development for tuberculosis. Science 311 (5765):: 1246-1247 doi:10.1126/science.1119299.
9. Boston Consulting Group (December 2008) Diseases of the developing world landscape. Slide 29.
10. Kola I, Landis J, (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 (8):: 711-715.
11. Struck MM, (1996) Vaccine R&D success rates and development timelines. Nat Biotechnol 14: 591-593.
12. Adams CP, Brantner VV, (2010) Spending on new drug development. Health Econ 19: 130-141.
13. DiMasi JA, Hansen RW, Grabowski HG, (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185.
14. Malaria Vaccine Initiative, PATH (2004) Clinical trials: crucial steps on the road to a malaria vaccine. August 2004. Rockville (MD): Malaria Vaccine Initiative, PATH. 5 p.
15. Sanofi Pasteur (n.d.) The vaccine development cycle. Available: http://www.sanofipasteur.com/sanofi-pasteur4/sp-media/SP_CORP4/EN/63/291/schema-cycle.pdf Accessed July 2011.
16. The Independent Institute (n.d.) The drug development and approval process. Available: http://www.fdareview.org/approval_process.shtml. Accessed July 2011.
17. Adams P (27 June 2011) After 40 years, RTS,S nears the finish line. TropIKA.net. Available: http://tropika.net/svc/review/Adams-20110627-Review-Malaria-rtss. Accessed 4 January 2012.
18. Janssen Research & Development, LLC (5 September 2012) U.S. FDA grants priority review to bedaquiline (TMC207) for multi-drug resistant tuberculosis treatment [press release].
19. PaxVax (19 March 2012) FDA accepts PaxVax's IND for single-dose oral cholera vaccine, company to begin phase 3 trials for first cholera vaccine candidate in U.S. [press release].
20. BIO Ventures for Global Health (2011) The vaccine landscape for neglected diseases: a perspective from the global health primer. April 2011. BIO Ventures for Global Health.
21. DiMasi J, (2001) New drug development in the United States from 1963 to 1999. Clin Pharm Ther 69: 286-296.
22. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, et al. (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359 (9324):: 2188-2194.
23. Robertson A, Stefanakis R, Joseph D, Moree M, (2012) The impact of the U.S. priority review voucher on private-sector investment in global health R&D. PLoS Negl Trop Dis 6: e1750 doi:10.1371/journal.pntd.0001750.
24. Rockoff JD, Winslow R, (11 July 2011) Drug makers refill parched pipelines. Wall Street Journal. July 11, 2011.